Great news from Achillion Pharmaceuticals, which recently celebrated the expansion of its New Haven Connecticut headquarters. The expansion was prompted by the company’s 20 percent growth in 2015. More growth is expected in the coming year.
“This expansion is the latest milestone in an exciting time for our company,” said Milind Deshpande, President and CEO of Achillion Pharmaceuticals at a gathering of colleagues and guests. “Since last year, we’ve partnered with Janssen Pharmaceuticals to advance our HCV portfolio and create next generation treatments for HCV, and we’ve brought our first factor D inhibitor into the clinic to potentially treat rare immunological diseases. We are proud that these compounds were discovered and developed here at our New Haven headquarters.”
Please see the full news release here for more information about Achillion and the expansion.
Based in New Haven, CT, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement inhibitors. Achillion is rapidly advancing its efforts to become a fully integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases.
Working off that Thanksgiving feast may be more important than you thought
November 23, 2016
Could Proton Pump Inhibitors Impair Activity of Capacitabine in GEC Patients?